CTS Corporation reported Q3 2026 sales of $149.6 million, up 5% year-over-year, with net income of $17.8 million (11.9% margin) and diluted EPS of $0.61. The company increased its 2026 guidance, projecting sales of $580-$590 million and adjusted diluted EPS of $2.78-$2.88.
Diversified end-market sales grew 7% and now represent 60% of total sales. The Millar acquisition advances the company's diversification strategy, particularly in the medical market.